Quince therapeutics presents safety data from prior phase 3 attest clinical trial at 53rd child neurology society annual meeting

South san francisco, calif.--(business wire)---- $qncx #biotech--quince therapeutics, inc. (nasdaq: qncx), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation at the 53rd child neurology society (cns) annual meeting of safety data from its prior phase 3 attest (ataxia-telangiectasia trial with the erydex system; #iedat-02-2015/nct02770807) clinical trial. the objective of the data analysis was to.
QNCX Ratings Summary
QNCX Quant Ranking